145 related articles for article (PubMed ID: 1686063)
1. Genetic polymorphism of debrisoquine oxidation: restriction fragment analysis and allele-specific amplification of mutant alleles of CYP2D6.
Heim MH; Meyer UA
Methods Enzymol; 1991; 206():173-83. PubMed ID: 1686063
[No Abstract] [Full Text] [Related]
2. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.
Daly AK; Armstrong M; Monkman SC; Idle ME; Idle JR
Pharmacogenetics; 1991 Oct; 1(1):33-41. PubMed ID: 1688241
[TBL] [Abstract][Full Text] [Related]
3. NcoI RFLP in the pseudogene (CYP2D8P) of the human debrisoquine 4-hydroxylase locus.
Mura C; Broyart JP; Jacqz E; Elion J; Krishnamoorthy R
Nucleic Acids Res; 1991 Mar; 19(5):1162. PubMed ID: 1673559
[No Abstract] [Full Text] [Related]
4. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.
Kimura S; Umeno M; Skoda RC; Meyer UA; Gonzalez FJ
Am J Hum Genet; 1989 Dec; 45(6):889-904. PubMed ID: 2574001
[TBL] [Abstract][Full Text] [Related]
5. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
Broly F; Meyer UA
Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
[TBL] [Abstract][Full Text] [Related]
6. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.
Steen VM; Andreassen OA; Daly AK; Tefre T; Børresen AL; Idle JR; Gulbrandsen AK
Pharmacogenetics; 1995 Aug; 5(4):215-23. PubMed ID: 8528268
[TBL] [Abstract][Full Text] [Related]
7. Detection of debrisoquine hydroxylation phenotypes.
Wolf CR; Moss JE; Miles JS; Gough AC; Spurr NK
Lancet; 1990 Dec; 336(8728):1452-3. PubMed ID: 1978915
[No Abstract] [Full Text] [Related]
8. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
Johansson I; Lundqvist E; Bertilsson L; Dahl ML; Sjöqvist F; Ingelman-Sundberg M
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11825-9. PubMed ID: 7903454
[TBL] [Abstract][Full Text] [Related]
9. Mutant debrisoquine hydroxylation genes in Parkinson's disease.
Armstrong M; Daly AK; Cholerton S; Bateman DN; Idle JR
Lancet; 1992 Apr; 339(8800):1017-8. PubMed ID: 1349052
[TBL] [Abstract][Full Text] [Related]
10. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene.
Løvlie R; Daly AK; Molven A; Idle JR; Steen VM
FEBS Lett; 1996 Aug; 392(1):30-4. PubMed ID: 8769309
[TBL] [Abstract][Full Text] [Related]
11. Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism.
Douglas AM; Atchison BA; Somogyi AA; Drummer OH
Pharmacogenetics; 1994 Jun; 4(3):154-8. PubMed ID: 7920695
[No Abstract] [Full Text] [Related]
12. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
13. Evolutionary pharmacogenetics of CYP2D6 in Ngawbe Guaymi of Panama: allele-specific PCR detection of the CYP2D6B allele and RFLP analysis.
Jorge LF; Arias TD; Griese U; Nebert DW; Eichelbaum M
Pharmacogenetics; 1993 Oct; 3(5):231-8. PubMed ID: 7904509
[TBL] [Abstract][Full Text] [Related]
14. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H
Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
[TBL] [Abstract][Full Text] [Related]
15. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis.
Broly F; Marez D; Sabbagh N; Legrand M; Millecamps S; Lo Guidice JM; Boone P; Meyer UA
Pharmacogenetics; 1995 Dec; 5(6):373-84. PubMed ID: 8747409
[TBL] [Abstract][Full Text] [Related]
16. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans.
Evans WE; Relling MV; Rahman A; McLeod HL; Scott EP; Lin JS
J Clin Invest; 1993 May; 91(5):2150-4. PubMed ID: 8098046
[TBL] [Abstract][Full Text] [Related]
17. A BamHI polymorphism in the human cytochrome P450 gene, CYP2D6.
Morimoto Y; Murayama N; Kuwano A; Yoshimura O; Kondo I
Clin Genet; 1995 Feb; 47(2):103-4. PubMed ID: 7606840
[No Abstract] [Full Text] [Related]
18. An association study of debrisoquine hydroxylase (CYP2D6) polymorphisms in schizophrenia.
Dawson E; Powell JF; Nöthen MM; Crocq MA; Lanczik M; Körner J; Rietschel M; van Os J; Wright P; Gill M
Psychiatr Genet; 1994; 4(4):215-8. PubMed ID: 7712118
[TBL] [Abstract][Full Text] [Related]
19. CYP2D6 genes and risk of liver cancer.
Agúndez JA; Ledesma MC; Benítez J; Ladero JM; Rodríguez-Lescure A; Díaz-Rubio E; Díaz-Rubio M
Lancet; 1995 Apr; 345(8953):830-1. PubMed ID: 7898230
[TBL] [Abstract][Full Text] [Related]
20. DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers.
Panserat S; Mura C; Gérard N; Vincent-Viry M; Galteau MM; Jacqz-Aigrain E; Krishnamoorthy R
Hum Genet; 1994 Oct; 94(4):401-6. PubMed ID: 7927337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
